Eli Lilly Earnings Preview

Analysts Expect Solid Q2

Eli Lilly and Co. (NYSE: LLY) is scheduled to report its second-quarter 2024 earnings on Thursday, August 8, 2024, after the market closes. Analysts expect the pharmaceutical giant to post strong results, driven by robust demand for its key products, including diabetes drug Trulicity and cancer drug Verzenio.

Key Metrics to Watch

According to FactSet, analysts expect Lilly to report sales of $10 billion for the quarter, representing a 6% increase year-over-year. Earnings per share (EPS) are projected to come in at $2.74, a 10% increase from the same period last year.

Investors will be closely watching Lilly's performance in key therapeutic areas, including diabetes, oncology, and immunology. The company's top-selling drug, Trulicity, is expected to continue to drive growth, while newer drugs like Verzenio and Jardiance are also expected to contribute to revenue.

Lilly's performance in international markets will also be in focus. The company has been expanding its presence in emerging markets, and investors will be looking for updates on its progress in these regions.

Overall, analysts are optimistic about Lilly's earnings prospects. The company has a strong pipeline of new drugs and a track record of consistent growth. Investors will be watching closely to see if Lilly can deliver another solid quarter and meet the expectations set by analysts.